Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Brainomix Announces New Phase III INBUILD® Data Highlighting Potential of Quantitative CT to Predict Disease Progression and Assess Treatment Response in Progressive Pulmonary Fibrosis

      Brainomix Logo

      News provided by

      Brainomix

      Oct 01, 2026, 07:00 ET

      Share this article

      Share this article


      • Published in the American Journal of Respiratory & Critical Care Medicine (AJRCCM), the analysis of 474 patients from Boehringer Ingelheim's Phase III INBUILD® HRCT sub-study represents the largest prospective evaluation of quantitative CT in patients with progressive pulmonary fibrosis (PPF) to date.
      • Researchers used Brainomix e-Lung to assess quantitative CT measures. They found that these measures were sensitive to the effects of nintedanib from baseline to 24 weeks and 52 weeks, and associated with FVC decline at each timepoint, providing further evidence of the potential role of quantitative CT in assessing treatment response in PPF clinical trials.

      OXFORD, England and CHICAGO, Oct. 1, 2026 /PRNewswire/ -- Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced new data published in the esteemed American Journal of Respiratory & Critical Care Medicine (AJRCCM), in which researchers used Brainomix e-Lung to assess quantitative CT measures. The researchers demonstrated that these measures were sensitive to the effects of antifibrotic treatment and associated with clinically relevant disease progression and treatment response in patients with progressive pulmonary fibrosis (PPF).

      The study, an analysis of the INBUILD® HRCT sub-study involving 474 patients, evaluated quantitative CT measurements derived using both Brainomix e-Lung software and the University of California, Los Angeles (UCLA) research algorithm. This study is the first systematic assessment of two quantitative CT approaches on the same dataset: the UCLA QLF/QILD research algorithms in parallel with Brainomix e-Lung software. The broad consistency between the two methods provides important cross-validation of quantitative CT (qCT) for ILD clinical trials.

      The researchers showed that nintedanib had significant effects on changes in e-Lung Total Disease Extent (TDE) at both 24 and 52 weeks, with significant effects also observed for e-Lung Reticulovascular Score (RVS) and Weighted Reticulovascular Score (WRVS) at week 24. The analysis also found that higher baseline quantitative CT measurements – including TDE, RVS and WRVS – were associated with a greater rate of FVC decline over 52 weeks.

      Together, the findings demonstrate the potential value of quantitative CT in clinical trials: complementing conventional measures, such as FVC, by providing more sensitive and direct measures of pathological changes in the lung to stratify patients and evaluate treatment efficacy. By enabling more targeted assessment of disease progression and treatment response, quantitative CT could revolutionize the design of clinical trials focused on more sensitive and relevant mechanistic measures of disease activity, potentially accelerating the development and evaluation of new treatments for patients with PPF.

      The study's lead author, Professor Anand Devaraj, Consultant Thoracic Radiologist at Royal Brompton Hospital and Medical Director at Brainomix, said: "These findings add to the growing evidence that quantitative CT can provide important information about structural lung disease that may be complementary to conventional measures such as FVC. In this analysis of patients with PPF, quantitative CT measurements were associated with subsequent disease progression and were sensitive to the effects of antifibrotic treatment. The findings support the continued development and incorporation of quantitative CT as an objective biomarker for clinical trials and, potentially, for monitoring disease progression in clinical practice."

      Susanne Stowasser, MD, co-author of the study and Head of Clinical Development Pulmonology/Rheumatology at Boehringer Ingelheim International GmbH, said: "The INBUILD trial has provided important insights into the treatment of patients with progressive pulmonary fibrosis, and these new analyses demonstrate the potential value of quantitative CT as an additional measure of disease progression and treatment response. The ability to detect meaningful changes in lung structure alongside established clinical measures could help strengthen the evidence base for antifibrotic therapies and inform the design of future clinical trials."

      This study has not been evaluated by FDA.

      About Brainomix

      Brainomix is a global pioneer in AI-powered medical imaging, transforming medical images into actionable insights to enable more precise treatment decisions in stroke and lung disease. Founded as a spinout from the University of Oxford, Brainomix brings AI-powered precision medicine into clinical practice across more than 20 countries. Its flagship Brainomix 360 Stroke platform supports acute stroke assessment throughout the patient pathway and has been shown to expand patient access to life- and disability-saving stroke treatments. Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans using a configured clinical workflow. Quantification of CT features can enable clinicians to more easily identify visual changes over multiple timepoints.

      To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on LinkedIn.

      Contacts
      At the company
      Jeff Wyrtzen, Chief Marketing Officer
      [email protected]
      T +44 (0)1865 582730

      Media Enquiries
      USA
      Jordyn Temperato
      LifeSci Communications
      [email protected] 

      UK & Europe
      Sue Charles
      Charles Consultants
      [email protected]

      SOURCE Brainomix

      Modal title

      Also from this source

      Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients

      Brainomix AI Imaging Analysis of Phase 3 CHARM Trial Identifies Promising Treatment Signals in Severe Stroke Patients

      Brainomix, a leading medtech company specializing in AI-powered imaging tools for stroke and lung disease, and Remedy Pharmaceuticals, Inc., a...

      Brainomix Multicenter Study Demonstrates Potential of Quantitative CT for Earlier Detection of Progressive Pulmonary Fibrosis (PPF)

      Brainomix Multicenter Study Demonstrates Potential of Quantitative CT for Earlier Detection of Progressive Pulmonary Fibrosis (PPF)

      Brainomix, a leading medtech company specializing in AI-powered imaging tools for lung disease and stroke, today announced the publication of new...

      More Releases From This Source

      Explore

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.